Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 05 - 05 tags : Clinical-trials-phase-ii save search
Amylyx Augments Case for ALS Drug Ahead of PDUFA Date
Published: 2022-05-05 (Crawled : 22:00) - biospace.com/
CLNN 4 | $0.3374 0.69% 0.68% 300K
|
|
| O: 0.0%
H: 0.32%
C: -7.96%
drug pdufa als
Amylyx Pharmaceuticals Announces Publication of New CENTAUR Trial Analyses Further Demonstrating Significant Survival Benefit with AMX0035 in People with ALS
Published: 2022-05-05 (Crawled : 18:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: -0.79%
H: 1.1%
C: -7.57%
amx0035 als trial publication
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
Published: 2022-05-05 (Crawled : 13:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.55%
H: 0.0%
C: -1.16%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.72%
H: 0.0%
C: 0.0%
ARCT 4 | $27.0 -3.33% -3.44% 270K
|
Health Technology
|
| O: 6.93%
H: 1.13%
C: -8.47%
arct-154 trial results
Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Published: 2022-05-05 (Crawled : 13:00) - biospace.com/
ALZN | $0.729 0.47% 0.47% 20K
|
Professional, Scientific, and T...
|
| O: 3.52%
H: 4.85%
C: 2.91%
al001 treatment dementia trial alzheimer’s alzheimer's
Belite Bio Presented Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022
Published: 2022-05-05 (Crawled : 13:00) - biospace.com/
BLTE | $37.23 0.62% 0.62% 33K
|
n/a
|
| O: 6.14%
H: 12.0%
C: 8.5%
lbs-008 results phase 2b
Moleculin Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
Published: 2022-05-05 (Crawled : 13:00) - biospace.com/
MBRX | $4.6 3.37% 7.4K
|
Health Technology
|
| O: -0.64%
H: 0.65%
C: -3.87%
treatment leukemia phase 1 acute myeloid leukemia aml
Global Roundup: FDA Hits Junshi, HUTCHMED with Complete Response Letters
Published: 2022-05-05 (Crawled : 12:00) - biospace.com/
IMMP | $2.59 3.19% 3.09% 1.4M
|
Health Technology
|
| O: -6.06%
H: 5.85%
C: -1.61%
fda response
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.